This document is the Japan Circulation Society and Japan Heart Failure Society Joint Guideline for the Diagnosis and Treatment of Acute and Chronic Heart Failure, an update of the 2017 version of the guideline.
This is the 2021 focused update of the JCS/JHFS guideline on the diagnosis and treatment of acute and chronic heart failure, revising the 2017 version. It begins with a chapter on definitions and classification, including heart failure types defined by left ventricular ejection fraction (HFrEF, HFpEF, HFmrEF) and by changes in ejection fraction over time (HFrecEF, HFworEF, HFuncEF), followed by a treatment algorithm.
Later chapters cover drug therapy (ivabradine as an If channel inhibitor, ARNI, SGLT2 inhibitors, and drugs for HFrEF), catheter-based treatment of mitral regurgitation with the MitraClip system, comorbid atrial fibrillation and renal failure, transcatheter aortic valve implantation and the Impella pump, and new drugs such as vericiguat and omecamtiv mecarbil. The document also explains how classes of recommendation, evidence levels and Minds grades are used. This manual is written in Japanese.
It divides heart failure into HFrEF, HFpEF and HFmrEF according to left ventricular ejection fraction, with additional categories for changes in LVEF over time.
Angiotensin receptor neprilysin inhibitor.
Sodium glucose cotransporter 2.
Transcatheter aortic valve implantation.